CA2086325C - Ligand pour le recepteur cd28 sur les cellules b et methodes - Google Patents

Ligand pour le recepteur cd28 sur les cellules b et methodes Download PDF

Info

Publication number
CA2086325C
CA2086325C CA2086325A CA2086325A CA2086325C CA 2086325 C CA2086325 C CA 2086325C CA 2086325 A CA2086325 A CA 2086325A CA 2086325 A CA2086325 A CA 2086325A CA 2086325 C CA2086325 C CA 2086325C
Authority
CA
Canada
Prior art keywords
cells
antigen
receptor
amino acid
ligand
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CA2086325A
Other languages
English (en)
Other versions
CA2086325A1 (fr
Inventor
Peter S. Linsley
Jeffrey A. Ledbetter
Nitin K. Damle
William Brady
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of CA2086325A1 publication Critical patent/CA2086325A1/fr
Application granted granted Critical
Publication of CA2086325C publication Critical patent/CA2086325C/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70532—B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Dans cette invention, on identifie l'antigène B7 comme ligand réactif pour le récepteur CD28 sur les cellules T. On y décrit des fragments et des dérivés de l'antigène B7 et du récepteur CD28, y compris des protéines hybrides ayant des séquences d'acides aminés correspondant aux domaines extracellulaires de B7 ou de CD28 jointes à des séquences d'acides aminés encodant des portions de l'immunoglobuline humaine C.gamma.1. On y fournit des méthodes pour utiliser l'antigène B7, ses fragments et ses dérivés, et le récepteur CD28, ses fragments et ses dérivés, ainsi que des anticorps et d'autres molécules réactifs avec l'antigène B7 et/ou le récepteur CD28, afin de réguler les réponses positives des cellules T au CD28 et des réponses immunitaires assistées par les cellules T. L'invention comprend aussi une méthode pour une épreuve de détection de ligands réactifs avec les récepteurs cellulaires favorisant l'adhésion intercellulaire.
CA2086325A 1990-07-02 1991-07-01 Ligand pour le recepteur cd28 sur les cellules b et methodes Expired - Lifetime CA2086325C (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US54798090A 1990-07-02 1990-07-02
US547,980 1990-07-02
US72210191A 1991-06-27 1991-06-27
US722,101 1991-06-27
PCT/US1991/004682 WO1992000092A1 (fr) 1990-07-02 1991-07-01 Ligand pour recepteur a cd28 sur des lymphocytes b et procedes

Publications (2)

Publication Number Publication Date
CA2086325A1 CA2086325A1 (fr) 1992-01-03
CA2086325C true CA2086325C (fr) 2010-10-05

Family

ID=27068718

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2086325A Expired - Lifetime CA2086325C (fr) 1990-07-02 1991-07-01 Ligand pour le recepteur cd28 sur les cellules b et methodes

Country Status (4)

Country Link
EP (1) EP0537293A4 (fr)
JP (2) JPH06508501A (fr)
CA (1) CA2086325C (fr)
WO (1) WO1992000092A1 (fr)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6352694B1 (en) 1994-06-03 2002-03-05 Genetics Institute, Inc. Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
US5858358A (en) * 1992-04-07 1999-01-12 The United States Of America As Represented By The Secretary Of The Navy Methods for selectively stimulating proliferation of T cells
US6534055B1 (en) 1988-11-23 2003-03-18 Genetics Institute, Inc. Methods for selectively stimulating proliferation of T cells
US7479269B2 (en) 1988-11-23 2009-01-20 Genetics Institute, Llc Methods for selectively enriching TH1 and TH2 cells
US6905680B2 (en) 1988-11-23 2005-06-14 Genetics Institute, Inc. Methods of treating HIV infected subjects
JP2546544B2 (ja) * 1989-10-27 1996-10-23 アーチ ディベラップメント コーポレイション 免疫強化を促進するための方法と組成物
US6406696B1 (en) 1989-10-27 2002-06-18 Tolerance Therapeutics, Inc. Methods of stimulating the immune system with anti-CD3 antibodies
WO1992015671A1 (fr) * 1991-03-08 1992-09-17 Cytomed, Inc. Proteines cd28 solubles et procedes de traitement au moyen desdites proteines
US5637481A (en) 1993-02-01 1997-06-10 Bristol-Myers Squibb Company Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell
JPH07508711A (ja) * 1992-04-07 1995-09-28 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン Ｃｄ２８経路免疫調節
US5747034A (en) * 1992-07-09 1998-05-05 Chiron Corporation Methods and materials for the induction of T cell anergy
ATE258595T1 (de) * 1992-07-09 2004-02-15 Chiron Corp Verfahren zur erzeugung von antikörpern gegen zelloberflächenmoleküle
US5397703A (en) * 1992-07-09 1995-03-14 Cetus Oncology Corporation Method for generation of antibodies to cell surface molecules
DK0600591T3 (da) * 1992-10-02 2003-08-25 Bristol Myers Squibb Co Inhibering af tumorcellevækst via indgivelse af B7-transfektede celler
US5718883A (en) * 1993-04-14 1998-02-17 The United States Of America As Represented By The Secretary Of The Navy Transgenic animal model for autoimmune diseases
US6491916B1 (en) 1994-06-01 2002-12-10 Tolerance Therapeutics, Inc. Methods and materials for modulation of the immunosuppresive activity and toxicity of monoclonal antibodies
DK0700430T3 (da) * 1993-06-04 2005-08-15 Us Navy Fremgangsmåder til selektivt af stimulere proliferation af T-celler
US6824779B1 (en) 1993-07-26 2004-11-30 Dana-Farber Cancer Institute, Inc. Methods for inhibiting the interaction of B7-2 with its natural ligand
US6084067A (en) 1993-07-26 2000-07-04 Dana-Farber Cancer Institute CTLA4/CD28 ligands and uses therefor
JPH0779793A (ja) * 1993-09-14 1995-03-28 Sumitomo Electric Ind Ltd Ｂ７０分子に対するモノクローナル抗体
US6218510B1 (en) * 1994-03-02 2001-04-17 Brigham & Woman's Hospital B7-1 and B7-2 polypeptides
ATE197766T1 (de) 1994-03-08 2000-12-15 Dana Farber Cancer Inst Inc VERFAHREN ZUR MODULATION VON ßT-ZELL-ANERGYß
DK0758383T3 (da) 1994-05-06 2007-05-29 Roussy Inst Gustave Oplöselige polypeptidfraktioner af LAG-3-proteinet; fremgangsmåde til fremstilling; terapeutisk sammensætning; antiidiotypisk antistof
US7175843B2 (en) 1994-06-03 2007-02-13 Genetics Institute, Llc Methods for selectively stimulating proliferation of T cells
WO1996013584A1 (fr) * 1994-11-01 1996-05-09 Targeted Genetics Corporation Recepteurs chimeres servant a produire des lymphocites t cytotoxique th, activables selectivement independants des cellules auxiliaires
US5576423A (en) 1994-12-02 1996-11-19 Schering Corporation Antibodies to the slam protein expressed on activated T cells
ATE384127T1 (de) 1994-12-02 2008-02-15 Schering Corp Kostimulatorisches t-zell-oberflächen-antigen slam
US5877021A (en) * 1995-07-07 1999-03-02 Ribozyme Pharmaceuticals, Inc. B7-1 targeted ribozymes
US7041634B2 (en) 1995-09-27 2006-05-09 Emory University Method of inhibiting immune system destruction of transplanted viable cells
JP4751493B2 (ja) * 1996-03-20 2011-08-17 ブリストル−マイヤーズ スクイッブ カンパニー Ｇｐ３９／ｃｄ４０およびｃｔｌａ４／ｃｄ２８／ｂ７経路のブロックによって免疫反応を阻止する方法およびそれに使用する組成物
GB9607711D0 (en) * 1996-04-13 1996-06-19 Univ Sheffield T-cell dependent vaccine
CA2194814A1 (fr) 1997-01-10 1998-07-10 Terry L. Delovitch Stimulation des cellules t protectrices pour prevenir les maladies auto-immunes
CA2292760A1 (fr) 1997-06-04 1998-12-10 Oxford Biomedica (Uk) Limited Vecteur
US7078512B2 (en) 1998-05-01 2006-07-18 Schering-Plough Animal Health Corporation Nucleic acid encoding feline CD86
US7279168B2 (en) 1998-05-01 2007-10-09 Texas A & M University System Recombinant virus expressing foreign DNA encoding feline CD86 and uses thereof
DE19905501B4 (de) 1999-02-10 2005-05-19 MediGene AG, Gesellschaft für molekularbiologische Kardiologie und Onkologie Verfahren zur Herstellung eines rekombinanten Adeno-assoziierten Virus, geeignete Mittel hierzu sowie Verwendung zur Herstellung eines Arzneimittels
EP1234031B2 (fr) 1999-11-30 2021-11-24 Mayo Foundation For Medical Education And Research Nouvelle molécule immunorégulatrice b7-h1,
US7030219B2 (en) * 2000-04-28 2006-04-18 Johns Hopkins University B7-DC, Dendritic cell co-stimulatory molecules
DE60132699T2 (de) 2000-06-06 2009-01-29 Bristol-Myers Squibb Co. Nukleinsäuren und polypeptide, die sich auf b7 beziehen und ihre verwendungen zur immunmodulierung
DE60143535D1 (de) 2000-10-02 2011-01-05 Novartis Vaccines & Diagnostic Humane antikörper gegen cd40
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US7829084B2 (en) 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
US7531168B2 (en) 2001-02-16 2009-05-12 Genetics Institute Llc Method for downmodulating immune response in type I diabetes
US7432351B1 (en) 2002-10-04 2008-10-07 Mayo Foundation For Medical Education And Research B7-H1 variants
US7754209B2 (en) 2003-07-26 2010-07-13 Trubion Pharmaceuticals Binding constructs and methods for use thereof
CA2943949C (fr) 2004-10-06 2020-03-31 Mayo Foundation For Medical Education And Research B7-h1 et procedes de diagnostic, de pronostic et de traitement du cancer
SG177944A1 (en) 2005-07-11 2012-02-28 Macrogenics Inc Methods for the treatment of autoimmune disorders using immunosuppressive monoclonal antibodies with reduced toxicity
CN105012953B (zh) 2005-07-25 2018-06-22 阿普泰沃研发有限责任公司 用cd37-特异性和cd20-特异性结合分子减少b-细胞
RU2487888C2 (ru) 2006-06-12 2013-07-20 ЭМЕРДЖЕНТ ПРОДАКТ ДИВЕЛОПМЕНТ СИЭТЛ, ЭлЭлСи Одноцепочечные мультивалентные связывающие белки с эффекторной функцией
WO2007147090A2 (fr) 2006-06-14 2007-12-21 Macrogenics, Inc. Procédés de traitement de troubles auto-immuns utilisant des anticorps monoclonaux à toxicité réduite
EP2514762B1 (fr) 2007-07-13 2015-04-08 The Johns Hopkins University Variants de B7-DC
ATE513856T1 (de) 2008-04-11 2011-07-15 Emergent Product Dev Seattle Cd37-immuntherapeutikum und kombination mit bifunktionellem chemotherapeutikum davon
EP2804619B1 (fr) * 2012-01-16 2021-10-13 Atox Bio Ltd. Reltecimod utilisés pour traiter des infections bactériennes
US9302005B2 (en) 2013-03-14 2016-04-05 Mayo Foundation For Medical Education And Research Methods and materials for treating cancer
EP3052131B1 (fr) 2013-10-01 2018-12-05 Mayo Foundation for Medical Education and Research Procédés de traitement du cancer chez des patients présentant des taux élevés de bim
WO2015179654A1 (fr) 2014-05-22 2015-11-26 Mayo Foundation For Medical Education And Research Distinction d'anticorps anti-b7-h1 agonistes et antagonistes
WO2016014148A1 (fr) 2014-07-23 2016-01-28 Mayo Foundation For Medical Education And Research Ciblage d'adn-pkcs et de b7-h1 pour traiter le cancer
CA2999138C (fr) 2015-09-21 2024-05-21 Aptevo Research And Development Llc Polypeptides de liaison a cd3
WO2017075045A2 (fr) 2015-10-30 2017-05-04 Mayo Foundation For Medical Education And Research Anticorps anti-b7-h1

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2003455C (fr) * 1988-11-23 2000-02-22 Craig B. Thompson Methode d'immunotherapie par stimulation des cd28
ZA91463B (en) * 1990-01-25 1992-09-30 Bristol Myers Squibb Co Method of activating cytolytic activity of lymphocytes using anti-cd28 antibody
WO1992015671A1 (fr) * 1991-03-08 1992-09-17 Cytomed, Inc. Proteines cd28 solubles et procedes de traitement au moyen desdites proteines

Also Published As

Publication number Publication date
EP0537293A4 (en) 1993-09-08
JP2002186486A (ja) 2002-07-02
EP0537293A1 (fr) 1993-04-21
WO1992000092A1 (fr) 1992-01-09
JPH06508501A (ja) 1994-09-29
CA2086325A1 (fr) 1992-01-03

Similar Documents

Publication Publication Date Title
CA2086325C (fr) Ligand pour le recepteur cd28 sur les cellules b et methodes
US5521288A (en) CD28IG fusion protein
US5968510A (en) CTLA4 receptor and uses thereof
AU661854B2 (en) CTL4A receptor, fusion proteins containing it and uses thereof
CA2113744C (fr) Methodes de regulation de la reponse immunitaire par des molecules fixatrices de ctla4 et des molecules fixatrices d'il4
US5844095A (en) CTLA4 Ig fusion proteins
US7572772B2 (en) Soluble CTLA4 mutant molecules
EP0682039A1 (fr) Des molécules CTLA4 et des molécules liant à IL4, et leurs utilisations
US6830937B1 (en) Method for generating and identifying antibodies directed against a B7
US20030219446A1 (en) Ligand for CD28 receptor on B cells and methods
MXPA95001794A (en) Ctla4 molecules and il-4 link molecules and uses of mis

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry